市场调查报告书
商品编码
1403460
2030 年水凝胶敷料市场预测:按产品、材料、应用、最终用户和地区分類的全球分析Hydrogel Dressing Market Forecasts to 2030 - Global Analysis By Product, Material, Application, End User and By Geography |
根据Stratistics MRC预测,2023年全球水凝胶敷料市场规模将达4,625亿美元,预计2030年将达到7,643亿美元,预测期内复合年增长率为7.4%。
水凝胶敷料是一种高含水量的医用材料,旨在促进创伤治疗并保持湿润的环境。水凝胶敷料具有多种优点,包括冷却效果、缓解疼痛和防止伤口脱水。水凝胶敷料可有效治疗多种类型的伤口,包括烧伤、溃疡和擦伤。
根据国际糖尿病联盟(IDF)统计,截至2020年2月,有4.63亿人患有糖尿病。
人们普遍认识到水凝胶敷料可促进组织修復和细胞增殖的最佳条件,因此将其纳入标准创伤护理方案中。水凝胶敷料已透过包括网路和医疗保健专业人员在内的各种管道普及,以帮助改善个人的健康。此外,医疗保健提供者现在能够就伤口管理做出更资讯的决定,并认识到保持湿润癒合环境的重要性。
由于使用尖端材料和技术,开发含有新型添加剂和专用聚合物的复杂水凝胶配方需要很高的製造成本。此外,医院、诊所和医疗保健提供者在将水凝胶敷料纳入标准创伤护理方案时可能会面临财务挑战。这种经济负担可能会影响患者的依从性或有利于更经济的创伤护理选择,从而阻碍市场扩张。
科技进步有助于敷料有效地创造和维持创伤治疗的最佳环境,最终加速復原过程。敷料配备感测器和指示器,可监测各种伤口参数,例如 pH 值、温度和感染标记。包括奈米技术在内的材料科学和技术的不断创新,导致了具有增强性能的高度复杂的水凝胶配方的开发,从而推动了市场的扩张。
缺乏认识可能导致创伤护理程序不当和关键医疗设备的利用不足。大部分医疗保健专业人员和患者可能不完全了解水凝胶敷料的用途和好处。此外,认知度低导致需求低,导致水凝胶敷料无法进入市场或容易融入常规创伤护理程序,阻碍了该市场的成长。
COVID-19 的爆发对水凝胶敷料市场产生了一些负面影响。供应链中断和物流挑战影响了包括水凝胶敷料在内的医疗产品的供应。製造和分销的延迟以及对某些医疗保健产品的需求增加造成了不确定性。此外,医院在管理非新冠患者方面面临挑战,影响了先进创伤护理解决方案的常规使用。大流行造成的景气衰退导致医疗机构的预算紧张,从而缩小了市场规模。
预计结晶质水凝胶领域将占据最大份额。结晶质水凝胶由高含水量的凝胶组成,没有明确的形状,使其成为多种伤口类型的通用解决方案。它易于涂抹和去除,其清凉和舒缓作用可减少患者换药时的疼痛和不适。此外,这些敷料在维持湿润的伤口环境方面表现出色,促进促进癒合的最佳条件,从而显着推动该细分市场的成长。
腿部静脉溃疡部分预计将在预测期内实现最高的复合年增长率,因为它解决了与慢性静脉功能不全相关的特定治疗需求。该产品透过创造促进癒合过程的最佳湿润环境,在这些溃疡的治疗中发挥重要作用,包括经常发生在下肢的血液循环受损而造成的伤口。该领域的成长是由于医疗保健专业人员意识到水凝胶敷料在治疗腿部静脉溃疡方面的有效性,有助于改善患者的治疗结果和生活质量,从而推动了这一领域的成长。
由于强大的医疗基础设施、技术创新和先进创伤护理的积极方法,北美在预测期内占据了最大的市场占有率。在北美,我们透过治疗糖尿病和肥胖等慢性疾病来关注患者的治疗结果和护理品质。加拿大、墨西哥、美国和其他地方的研究表明,水凝胶配方的研究和开发仍在继续,以确保这些敷料满足医疗保健专业人员和患者不断变化的需求。我们正在支持该地区的发展。
预计欧洲在预测期内的复合年增长率最高。研究和开发有助于水凝胶配方的不断创新,提高其有效性并扩大其应用。欧洲法规结构保证医疗产品的安全性和有效性,并增强医疗保健专业人员和患者的信心。 3M 公司、强生服务公司、美敦力公司和施乐辉公司等主要企业公司在技术创新和实证医学方面发挥重要作用,进一步推动了该地区的扩张。
According to Stratistics MRC, the Global Hydrogel Dressing Market is accounted for $462.5 billion in 2023 and is expected to reach $764.3 billion by 2030 growing at a CAGR of 7.4% during the forecast period. A hydrogel dressing is a medical material with a high water content designed to promote wound healing and maintain a moist environment. Hydrogel dressings provide several benefits, including cooling effects, pain relief, and preventing wound dehydration. They are effective in managing various types of wounds, such as burns, ulcers, and abrasions.
According to International Diabetes Federation (IDF), as of February 2020, 463 million people were calculated to be living with diabetes.
The awareness that hydrogel dressings promote optimal conditions for tissue repair and cell proliferation has led to their integration into standard wound care protocols. These are promoted through various channels, including the internet and healthcare professionals, and empower individuals to advocate for their well-being. Furthermore, healthcare providers are now better equipped to make informed decisions about wound management, recognizing the significance of maintaining a moist healing environment.
The development of complex hydrogel formulations, which include novel additives and specialized polymers, involves high production costs as they are made using cutting-edge materials and technologies. In addition, hospitals, clinics, and healthcare providers may face financial challenges when incorporating hydrogel dressings into their standard wound care protocols. This financial burden may influence patient compliance and preference for more economical wound care options, hampering this market expansion.
The technological enhancements contribute to the dressings' efficacy in creating and maintaining an optimal environment for wound healing, ultimately accelerating the recovery process. These are equipped with sensors or indicators that monitor various wound parameters, such as pH levels, temperature, and infection markers. Continuous innovation in materials science technologies such as nanotechnology has led to the development of highly sophisticated hydrogel formulations with enhanced properties, which are driving this market expansion.
A lack of awareness may result in inadequate wound care procedures and inadequate use of a significant medical tool. It's possible that a sizable percentage of medical professionals and patients are not fully aware of the uses and advantages of hydrogel dressings. Additionally, low awareness can lead to low demand, which prevents hydrogel dressings from entering the market and from being easily incorporated into regular wound care routines, which is hindering this market's growth.
The COVID-19 pandemic has had several negative impacts on the hydrogel dressing market. Supply chain disruptions and logistic challenges affected the availability of medical products, including hydrogel dressings. Manufacturing and distribution delays, as well as increased demand for certain healthcare products, contributed to uncertainties. In addition, hospitals faced challenges in managing non-COVID patients, impacting the regular utilization of advanced wound care solutions. The economic downturn associated with the pandemic resulted in budget constraints for healthcare facilities, thereby impeding this market size.
The amorphous hydrogel segment is estimated to hold the largest share. These are composed of a high-water-content gel without a defined shape and are versatile solutions for various wound types. This is often preferred for managing partial-thickness burns, abrasions, and donor sites due to its ease of application and gentle removal, which offer cooling and soothing effects, reducing pain and discomfort for patients during dressing changes. Furthermore, these dressings excel at maintaining a moist wound environment, promoting optimal conditions for accelerated healing, thereby significantly driving this segment's growth.
The venous leg ulcer segment is anticipated to have highest CAGR during the forecast period, due to its ability to address a specific therapeutic need associated with chronic venous insufficiency. This plays a major role in managing these ulcers by creating an optimally moist environment that facilitates the healing process, including wounds caused by impaired blood circulation, often occurring in the lower extremities. As healthcare professionals increasingly recognize the efficacy of hydrogel dressings in managing venous leg ulcers, it is contributing to improved outcomes and quality of life for patients, which is boosting this segment expansion.
North America commanded the largest market share during the extrapolated period owing to a robust healthcare infrastructure, technological innovation, and a proactive approach to advanced wound care. They focused on patient outcomes and quality of care by treating chronic conditions, including diabetes and obesity. Regions such as Canada, Mexico, and the United States lead to continuous research and development in hydrogel formulations, ensuring that these dressings meet the evolving needs of healthcare providers and patients, which is boosting this region's growth.
Europe is expected to witness highest CAGR over the projection period. Research and development contribute to the continuous innovation of hydrogel formulations, enhancing their effectiveness and expanding their applications. Regulatory frameworks in Europe ensure the safety and efficacy of medical products, instilling confidence in healthcare professionals and patients alike. Key players, including 3M Company, Johnson & Johnson Services, Inc., Medtronic plc, and Smith & Nephew plc, play a major role in contributing technological innovations and evidence-based medicine, which further propel this region's expansion.
Some of the key players in the Hydrogel Dressing Market include 3M Company, Axelgaard Manufacturing Co Ltd, Convatec Group plc, B Braun Melsungen AG (B. Braun Holding GmbH & Co. KG), Integra LifeSciences, Hollister Incorporated, Lohmann & Rauscher GmbH & Co. KG, McKesson Corporation, Medline Industries LP, Procyon Corporation, Smith & Nephew plcand Amerx health care corp.
In August 2023, 3M announced that it has reached an agreement with the court-appointed negotiating plaintiffs' counsel to resolve the Combat Arms Earplug litigation against Aearo Technologies (Aearo) and 3M.
In September 2023, Procyon Advisors LLC had acquired a new position in the shares of ON Semiconductor Corporation during the second quarter.
In July 2023, Convatec Group Plc announced its collaboration with Tandem Diabetes Care on a new five-inch infusion set for Tandem Mobi, the world's smallest durable automated insulin delivery system that has now been FDA 510(k) cleared3.